Fig. 1 · Structure

Documents & Downloads

Adenosine

Cat. No. A10040 CAS 58-61-7
Adenosine plays an important role in biochemical processes, such as energy transfer-as adenosine triphosphate (ATP) and adenosine diphosphate (ADP)-as well as in signal transduction as cyclic adenosine monophosphate, cAMP. It is also an inhibitory neurotransmitter.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Adenosine produces receptor-dependent physiological signaling. In mice lacking all four adenosine receptors (A1, A2A, A2B and A3), an acute adenosine challenge did not significantly alter the temperature or cardiovascular endpoints that changed in receptor-bearing controls. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Human Endogenous Metabolite  
Microbial Metabolite  

Adenosine Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Adenosine from 2 published references.

Adenosine In Vitro Studies

In mouse thalamocortical slices, 100 μM adenosine increased paired-pulse ratio and facilitation during ongoing stimulation. Median tuning-curve slope and membrane potential were not significantly changed, while variability in tuning-curve slope decreased. [2]

Adenosine modulation of thalamocortical short-term plasticity

Cell-based study · Ex vivo thalamocortical slices from male and female ICR mice, postnatal days 14–25; layer 4 regular-spiking neurons [2]

Bath-applied adenosine increased paired-pulse ratio and facilitation index. Median tuning-curve slope and membrane potential did not change significantly, although tuning-curve variability decreased. The pattern is consistent with presynaptic modulation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Paired-pulse ratioDirection and P value Increased; p = 0.024; n = 11[2]
Facilitation index during ongoing stimulationDirection and P value Increased; p = 0.0049; n = 11[2]
Median tuning-curve slopeP value No significant change; p = 0.97; n = 11[2]
Variability of tuning-curve slopeDirection and P value Decreased; p = 0.0009[2]
Membrane potentialMedian depolarization 0.97 mV; p = 0.24; n = 11[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
Bath application during whole-cell recordings at 24°C; paired comparison with pre-application control ACSF
Vehicle
Artificial cerebrospinal fluid (ACSF) bath; adenosine stock solvent not specified
Co-treatment
No co-administered receptor antagonist in the selected adenosine comparison. Intracellular recording solution contained 1 mM DNDS to suppress GABAA-mediated responses.
Reported limits
Exact adenosine exposure/equilibration time and stock solvent not reported in the selected methods/results. n=11 recordings; number of contributing animals for this comparison not specified.
Methods and source locations

Compound reported in the paper: Adenosine; Compound label in the paper: ADO

Ex vivo neuronal pharmacology; no general cell-viability or in vivo efficacy claim.

Results: STP is Regulated by Presynaptic Adenosine Receptor Activation; Fig 2A–C and legend; Materials and Methods: Slice Preparation; Recordings; Electrical Stimulation; Analysis

Paired-pulse ratio: Whole-cell recordings before and after adenosine; Wilcoxon signed-rank test, except tuning-curve variability assessed by F-test. n refers to recordings. No effect size estimated from plotted points. — Fig 2A and Results

Facilitation index during ongoing stimulation: Whole-cell recordings before and after adenosine; Wilcoxon signed-rank test, except tuning-curve variability assessed by F-test. n refers to recordings. No effect size estimated from plotted points. — Fig 2B and Results

Median tuning-curve slope: Whole-cell recordings before and after adenosine; Wilcoxon signed-rank test, except tuning-curve variability assessed by F-test. n refers to recordings. No effect size estimated from plotted points. — Fig 2C and Results

Variability of tuning-curve slope: Whole-cell recordings before and after adenosine; Wilcoxon signed-rank test, except tuning-curve variability assessed by F-test. n refers to recordings. No effect size estimated from plotted points. — Fig 2C and Results

Membrane potential: Whole-cell recordings before and after adenosine; Wilcoxon signed-rank test, except tuning-curve variability assessed by F-test. n refers to recordings. No effect size estimated from plotted points. — Results paragraph beginning Adenosine reduces synaptic excitation

Adenosine In Vivo Studies

A single 100 mg/kg intraperitoneal adenosine challenge lowered body temperature, heart rate, mean arterial pressure and activity, and increased pulse pressure in female receptor-bearing control mice. These effects were not significant in quadruple adenosine-receptor knockout mice. The study measures acute pharmacodynamic responses rather than therapeutic efficacy. [1]

Acute physiological responses in adenosine-receptor knockout mice

Animal study · Female quadruple adenosine-receptor knockout mice and mixed-background receptor-bearing controls [1]

Adenosine changed temperature, cardiovascular readouts and activity in controls, while the tested responses were not significant in quadruple-knockout mice. This is pharmacodynamic evidence, not pharmacokinetics or disease-treatment efficacy. Germline adaptation and mixed genetic background limit interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Core body temperature, average 0–60 minDirection and adjusted P value Reduced in controls: P<0.0001; no significant effect in QKO[1]
Heart rate, average 0–30 minDirection and adjusted P value Reduced in controls: P=0.04; no significant effect in QKO[1]
Mean arterial pressure, average 0–30 minDirection and adjusted P value Reduced in controls: P=0.003; no significant effect in QKO[1]
Pulse pressure as percentage of systolic pressure, average 0–30 minDirection and adjusted P value Increased in controls: P=0.0002; no significant effect in QKO[1]
Activity, average 0–30 minDirection and adjusted P value Reduced in controls: P=0.003; no significant effect in QKO[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single acute challenge
Treatment course
Time course shown through 120 min after injection; temperature summary 0–60 min, other endpoints 0–30 min
Vehicle
10% DMSO in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Control mice
100 mg/kg
Vehicle-treated mice of the corresponding genotypeLower temperature, heart rate, mean arterial pressure and activity; higher pulse pressure versus vehicle.[1]
Quadruple receptor-knockout mice
100 mg/kg
Vehicle-treated mice of the corresponding genotypeNo significant adenosine effect on the five measured endpoints under these conditions.[1]
Control mice
Model: Female mixed-background controls, +/+ or +/− at all four adenosine-receptor loci
Reported limits: Exact age of Fig 2 cohort and injection volume not specified in the selected locations; N=3–5/group, not an endpoint-specific allocation. Error-bar definition is not specified in the Fig 2 legend.
Quadruple receptor-knockout mice
Model: Female Adora1−/−;Adora2a−/−;Adora2b−/−;Adora3−/− mice
Reported limits: Exact age of Fig 2 cohort and injection volume not specified in the selected locations; N=3–5/group, not an endpoint-specific allocation. Error-bar definition is not specified in the Fig 2 legend.
Methods and source locations

Compound reported in the paper: Adenosine; Compound label in the paper: Ado

Literature evidence for adenosine, not verification of Adooq material.

Results: Loss of adenosine-induced hypothermia, bradycardia, and hypotension in QKO mice; Fig 2A–E and legend; Materials and methods: Mice; Compounds; In vivo physiology; Discussion: Limitations

Core body temperature, average 0–60 min: Telemetry; vehicle versus adenosine within controls; two-way ANOVA with Sidak multiple comparisons; N=3–5/group. Activity analyzed after log transformation. Exact effect sizes not transcribed from curves. — Fig 2A (image and legend); In vivo physiology

Heart rate, average 0–30 min: Telemetry; vehicle versus adenosine within controls; two-way ANOVA with Sidak multiple comparisons; N=3–5/group. Activity analyzed after log transformation. Exact effect sizes not transcribed from curves. — Fig 2B (image and legend); In vivo physiology

Mean arterial pressure, average 0–30 min: Telemetry; vehicle versus adenosine within controls; two-way ANOVA with Sidak multiple comparisons; N=3–5/group. Activity analyzed after log transformation. Exact effect sizes not transcribed from curves. — Fig 2C (image and legend); In vivo physiology

Pulse pressure as percentage of systolic pressure, average 0–30 min: Telemetry; vehicle versus adenosine within controls; two-way ANOVA with Sidak multiple comparisons; N=3–5/group. Activity analyzed after log transformation. Exact effect sizes not transcribed from curves. — Fig 2D (image and legend); In vivo physiology

Activity, average 0–30 min: Telemetry; vehicle versus adenosine within controls; two-way ANOVA with Sidak multiple comparisons; N=3–5/group. Activity analyzed after log transformation. Exact effect sizes not transcribed from curves. — Fig 2E (image and legend); In vivo physiology

Control mice · Results: Loss of adenosine-induced hypothermia, bradycardia, and hypotension in QKO mice; Fig 2A–E and legend; Materials and methods: Mice; Compounds; In vivo physiology

Quadruple receptor-knockout mice · Results: Loss of adenosine-induced hypothermia, bradycardia, and hypotension in QKO mice; Fig 2A–E and legend; Materials and methods: Mice; Compounds; In vivo physiology

Specifications

Manufacturer Adooq Bioscience
CAS Number 58-61-7
Formula C10H13N5O4
Molecular Weight 267.24
SMILES
C1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 12 mg/mL (44.9 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Adenosine Research References

  1. [1] Xiao C, Liu N, Jacobson KA, et al. Physiology and effects of nucleosides in mice lacking all four adenosine receptors. PLoS biology (2019). PMID: 30822301 DOI: 10.1371/journal.pbio.3000161 Source material
  2. [2] Ferrati G, Martini FJ, Maravall M. Presynaptic Adenosine Receptor-Mediated Regulation of Diverse Thalamocortical Short-Term Plasticity in the Mouse Whisker Pathway. Frontiers in neural circuits (2016). PMID: 26941610 DOI: 10.3389/fncir.2016.00009 Source material

Added to your cart

View Cart Checkout
Loading...